CN118215684A - 与MerTK特异性结合的抗体或其片段及抗肿瘤剂 - Google Patents

与MerTK特异性结合的抗体或其片段及抗肿瘤剂 Download PDF

Info

Publication number
CN118215684A
CN118215684A CN202280069549.9A CN202280069549A CN118215684A CN 118215684 A CN118215684 A CN 118215684A CN 202280069549 A CN202280069549 A CN 202280069549A CN 118215684 A CN118215684 A CN 118215684A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
antibody
mertk
sequence represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280069549.9A
Other languages
English (en)
Chinese (zh)
Inventor
丰浦雅义
上林博明
泽田笃志
武居亚希
井上俊和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiome Bioscience Inc
Original Assignee
Chiome Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiome Bioscience Inc filed Critical Chiome Bioscience Inc
Publication of CN118215684A publication Critical patent/CN118215684A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202280069549.9A 2021-10-15 2022-09-16 与MerTK特异性结合的抗体或其片段及抗肿瘤剂 Pending CN118215684A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021169289 2021-10-15
JP2021-169289 2021-10-15
PCT/JP2022/034801 WO2023063026A1 (ja) 2021-10-15 2022-09-16 ＭｅｒＴＫに特異的に結合する抗体又はその断片、及び抗腫瘍剤

Publications (1)

Publication Number Publication Date
CN118215684A true CN118215684A (zh) 2024-06-18

Family

ID=85987671

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280069549.9A Pending CN118215684A (zh) 2021-10-15 2022-09-16 与MerTK特异性结合的抗体或其片段及抗肿瘤剂

Country Status (9)

Country Link
US (1) US20250326862A1 (https=)
EP (1) EP4417625A4 (https=)
JP (1) JPWO2023063026A1 (https=)
KR (1) KR20240082341A (https=)
CN (1) CN118215684A (https=)
AU (1) AU2022368026A1 (https=)
CA (1) CA3233968A1 (https=)
IL (1) IL311952A (https=)
WO (1) WO2023063026A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7211703B2 (ja) * 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
WO2020076799A1 (en) * 2018-10-09 2020-04-16 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
BR112021020867A2 (pt) * 2019-04-19 2022-01-04 Genentech Inc Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
JP2023506465A (ja) * 2019-12-13 2023-02-16 アレクトル エルエルシー 抗ＭｅｒＴＫ抗体及びその使用方法

Also Published As

Publication number Publication date
EP4417625A1 (en) 2024-08-21
IL311952A (en) 2024-06-01
EP4417625A4 (en) 2026-01-14
CA3233968A1 (en) 2023-04-20
WO2023063026A1 (ja) 2023-04-20
JPWO2023063026A1 (https=) 2023-04-20
US20250326862A1 (en) 2025-10-23
AU2022368026A1 (en) 2024-05-02
KR20240082341A (ko) 2024-06-10

Similar Documents

Publication Publication Date Title
US12297265B2 (en) Antibody and use thereof
JP6124377B2 (ja) 新規抗ｄｒ５抗体
AU2019415395A1 (en) Novel anti-CCR8 antibody
CN113993893A (zh) 新cd40结合抗体
US20160194402A1 (en) Cd70-binding peptides and method, process and use relating thereto
CA3056972A1 (en) Anti-ox40 antibody and use thereof
US20240301085A1 (en) Humanized gpc3 antibody and application thereof
EP4039704A1 (en) Anti-pd-1 antibody and use thereof
CN113906054A (zh) 能够结合cd19和cd3的多特异性抗原结合蛋白及其用途
JP2026016483A (ja) 抗ヒトｔｌｒ７抗体
CN118946592A (zh) 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
KR20240103034A (ko) Tigit 및 pd-l1에 대한 이중특이적 항체, 그의 의약 조성물, 및 그의 용도
CN110546165A (zh) 抗-pd-l1-抗-tim-3双特异性抗体
CN114790241B (zh) 抗tigit抗体及其应用
AU2017207082A1 (en) Anti-Myl9 antibody
KR20250084976A (ko) 항cd16a 항체 및 이의 적용
JP7846925B2 (ja) Ｃｄ２５を標的とする抗体及びその製造方法と応用
EP4483899A1 (en) Medicine comprising combination of anti-mutant-calr antibody and another drug
US20250215089A1 (en) Antigen-binding protein targeting pd-l1 and cd40, preparation therefor, and use thereof
KR20250167678A (ko) 이중특이적 항체 및 이의 응용
CN119874907A (zh) 抗人vsig4的抗体及其医药用途
CN118215684A (zh) 与MerTK特异性结合的抗体或其片段及抗肿瘤剂
CA3230246A1 (en) Bispecific antibody and use thereof
US20260116991A1 (en) Monoclonal antibody for specifically recognizing glypican-3, and application thereof
WO2023227115A1 (en) A method of treating solid tumor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination